A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study

J. Kellogg Parsons, Peter A. Pinto, Christian P. Pavlovich, Edward Uchio, Hyung L. Kim, Mikel N. Nguyen, James L. Gulley, Christina Jamieson, Chiu-Hsieh Hsu, Margarita Wojtowicz, Howard Parnes, Jeffrey Schlom, William L. Dahut, Ravi A. Madan, Renee N. Donahue, Hsiao-Hui Chow

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The Immunotherapy to Prevent Progression on Active Surveillance Study is the first trial of immunotherapy for localized prostate cancer. We randomized active surveillance patients to PSA-TRICOM (PROSTVAC) or placebo for 5 mo. Final results will be available in 2019.

Original languageEnglish (US)
JournalEuropean Urology Focus
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Immunotherapy
Prostatic Neoplasms
Placebos
PROSTVAC

ASJC Scopus subject areas

  • Urology

Cite this

A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer : The Immunotherapy to Prevent Progression on Active Surveillance Study. / Parsons, J. Kellogg; Pinto, Peter A.; Pavlovich, Christian P.; Uchio, Edward; Kim, Hyung L.; Nguyen, Mikel N.; Gulley, James L.; Jamieson, Christina; Hsu, Chiu-Hsieh; Wojtowicz, Margarita; Parnes, Howard; Schlom, Jeffrey; Dahut, William L.; Madan, Ravi A.; Donahue, Renee N.; Chow, Hsiao-Hui.

In: European Urology Focus, 01.01.2018.

Research output: Contribution to journalArticle

Parsons, J. Kellogg ; Pinto, Peter A. ; Pavlovich, Christian P. ; Uchio, Edward ; Kim, Hyung L. ; Nguyen, Mikel N. ; Gulley, James L. ; Jamieson, Christina ; Hsu, Chiu-Hsieh ; Wojtowicz, Margarita ; Parnes, Howard ; Schlom, Jeffrey ; Dahut, William L. ; Madan, Ravi A. ; Donahue, Renee N. ; Chow, Hsiao-Hui. / A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer : The Immunotherapy to Prevent Progression on Active Surveillance Study. In: European Urology Focus. 2018.
@article{867e2ad9d6744effa11c518dd4c66252,
title = "A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study",
abstract = "The Immunotherapy to Prevent Progression on Active Surveillance Study is the first trial of immunotherapy for localized prostate cancer. We randomized active surveillance patients to PSA-TRICOM (PROSTVAC) or placebo for 5 mo. Final results will be available in 2019.",
author = "Parsons, {J. Kellogg} and Pinto, {Peter A.} and Pavlovich, {Christian P.} and Edward Uchio and Kim, {Hyung L.} and Nguyen, {Mikel N.} and Gulley, {James L.} and Christina Jamieson and Chiu-Hsieh Hsu and Margarita Wojtowicz and Howard Parnes and Jeffrey Schlom and Dahut, {William L.} and Madan, {Ravi A.} and Donahue, {Renee N.} and Hsiao-Hui Chow",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.euf.2018.08.016",
language = "English (US)",
journal = "European Urology Focus",
issn = "2405-4569",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer

T2 - The Immunotherapy to Prevent Progression on Active Surveillance Study

AU - Parsons, J. Kellogg

AU - Pinto, Peter A.

AU - Pavlovich, Christian P.

AU - Uchio, Edward

AU - Kim, Hyung L.

AU - Nguyen, Mikel N.

AU - Gulley, James L.

AU - Jamieson, Christina

AU - Hsu, Chiu-Hsieh

AU - Wojtowicz, Margarita

AU - Parnes, Howard

AU - Schlom, Jeffrey

AU - Dahut, William L.

AU - Madan, Ravi A.

AU - Donahue, Renee N.

AU - Chow, Hsiao-Hui

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The Immunotherapy to Prevent Progression on Active Surveillance Study is the first trial of immunotherapy for localized prostate cancer. We randomized active surveillance patients to PSA-TRICOM (PROSTVAC) or placebo for 5 mo. Final results will be available in 2019.

AB - The Immunotherapy to Prevent Progression on Active Surveillance Study is the first trial of immunotherapy for localized prostate cancer. We randomized active surveillance patients to PSA-TRICOM (PROSTVAC) or placebo for 5 mo. Final results will be available in 2019.

UR - http://www.scopus.com/inward/record.url?scp=85052933323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052933323&partnerID=8YFLogxK

U2 - 10.1016/j.euf.2018.08.016

DO - 10.1016/j.euf.2018.08.016

M3 - Article

C2 - 30197041

AN - SCOPUS:85052933323

JO - European Urology Focus

JF - European Urology Focus

SN - 2405-4569

ER -